FibroBiologics, Inc. cotiza a 0.95 USD y tiene una capitalización bursátil de $7M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 wh…
| Periodo | 2026-07 | 2026-04 | 2026-02 | 2025-10 |
|---|---|---|---|---|
| Real | $-0.66 | $-1.33 | $-0.60 | $-2.60 |
| Estimado | $-0.93 | $-1.35 | $-2.00 | $-2.30 |
| Sorpresa | +29.0% | +1.5% | +70.0% | -13.0% |
| Métrica | FBLG | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -302.9% | -40.4% | -262.5% |
| ROA | -193.8% | -32.0% | -161.8% |
| Current Ratio | 3.61 | 2.84 | +0.77 |
| Debt / Equity | — | 0.28 | — |